OBJECTIVE:Individual blood pressure responses to antihypertensive therapy are difficult to predict. To improve optimization of antihypertensive therapy, we analyzed correlations of relevant laboratory tests with blood pressure responses to four antihypertensive monotherapies. METHODS: In the GENRES study, 208 Finnish men aged 35-60 years with moderate hypertension usedamlodipine 5 mg, bisoprolol 5 mg, hydrochlorothiazide 25 mg and losartan 50 mg daily, each for 4 weeks as a monotherapy in a double-blind, randomized, placebo-controlled crossover study; that is, each subject received each type of monotherapy in a random order. The treatment periods were preceded and separated by 4-week placebo periods. Ambulatory 24-h and office blood pressure measurements were carried out after all study periods. Data from several biochemical tests were correlated to antihypertensive drug responses. RESULTS:Serum total calcium concentration was negatively correlated with blood pressure responses to amlodipine (P values 0.001-0.002). Plasma renin activity was positively correlated with blood pressure responses to losartan (P values 0.001-0.005) and bisoprolol (P values 0.03-0.17), and negatively with blood pressure responses to hydrochlorothiazide (P values 0.01-0.07). Daily urinary excretion of sodium was negatively correlated with ambulatory blood pressure responses to amlodipine (P values 0.001-0.01). CONCLUSIONS: In this carefully controlled study, marked individual variations in antihypertensive drug responsiveness were found to correlate to several baseline laboratory parameters. The negative correlation between serum calcium levels and amlodipine responses is intriguing and suggests an underlying mechanistic association. Collectively, our data imply that laboratory tests may have some value in prediction of the efficacy of various antihypertensive drug therapies, although great patient-to-patient variation remains an obstacle for exact predictive classification.
RCT Entities:
OBJECTIVE: Individual blood pressure responses to antihypertensive therapy are difficult to predict. To improve optimization of antihypertensive therapy, we analyzed correlations of relevant laboratory tests with blood pressure responses to four antihypertensive monotherapies. METHODS: In the GENRES study, 208 Finnish men aged 35-60 years with moderate hypertension used amlodipine 5 mg, bisoprolol 5 mg, hydrochlorothiazide 25 mg and losartan 50 mg daily, each for 4 weeks as a monotherapy in a double-blind, randomized, placebo-controlled crossover study; that is, each subject received each type of monotherapy in a random order. The treatment periods were preceded and separated by 4-week placebo periods. Ambulatory 24-h and office blood pressure measurements were carried out after all study periods. Data from several biochemical tests were correlated to antihypertensive drug responses. RESULTS: Serum total calcium concentration was negatively correlated with blood pressure responses to amlodipine (P values 0.001-0.002). Plasma renin activity was positively correlated with blood pressure responses to losartan (P values 0.001-0.005) and bisoprolol (P values 0.03-0.17), and negatively with blood pressure responses to hydrochlorothiazide (P values 0.01-0.07). Daily urinary excretion of sodium was negatively correlated with ambulatory blood pressure responses to amlodipine (P values 0.001-0.01). CONCLUSIONS: In this carefully controlled study, marked individual variations in antihypertensive drug responsiveness were found to correlate to several baseline laboratory parameters. The negative correlation between serum calcium levels and amlodipine responses is intriguing and suggests an underlying mechanistic association. Collectively, our data imply that laboratory tests may have some value in prediction of the efficacy of various antihypertensive drug therapies, although great patient-to-patient variation remains an obstacle for exact predictive classification.
Authors: Daniel H Katz; Rahul C Deo; Frank G Aguilar; Senthil Selvaraj; Eva E Martinez; Lauren Beussink-Nelson; Kwang-Youn A Kim; Jie Peng; Marguerite R Irvin; Hemant Tiwari; D C Rao; Donna K Arnett; Sanjiv J Shah Journal: J Cardiovasc Transl Res Date: 2017-03-03 Impact factor: 4.132
Authors: Marja-Liisa Nuotio; Heini Sánez Tähtisalo; Alexandra Lahtinen; Kati Donner; Frej Fyhrquist; Markus Perola; Kimmo K Kontula; Timo P Hiltunen Journal: Epigenetics Date: 2022-02-25 Impact factor: 4.861
Authors: F Gueyffier; F Subtil; T Bejan-Angoulvant; Y Zerbib; J P Baguet; J M Boivin; A Mercier; G Leftheriotis; J P Gagnol; J P Fauvel; C Giraud; G Bricca; D Maucort-Boulch; S Erpeldinger Journal: J Hum Hypertens Date: 2014-04-17 Impact factor: 3.012
Authors: Timo P Hiltunen; Kati M Donner; Antti-Pekka Sarin; Janna Saarela; Samuli Ripatti; Arlene B Chapman; John G Gums; Yan Gong; Rhonda M Cooper-DeHoff; Francesca Frau; Valeria Glorioso; Roberta Zaninello; Erika Salvi; Nicola Glorioso; Eric Boerwinkle; Stephen T Turner; Julie A Johnson; Kimmo K Kontula Journal: J Am Heart Assoc Date: 2015-01-26 Impact factor: 5.501
Authors: Timo P Hiltunen; Jenni M Rimpelä; Robert P Mohney; Steven M Stirdivant; Kimmo K Kontula Journal: PLoS One Date: 2017-11-09 Impact factor: 3.240
Authors: Lauri Suojanen; Antti Haring; Antti Tikkakoski; Heini Huhtala; Mika Kähönen; Arttu Eräranta; Jukka T Mustonen; Ilkka H Pörsti Journal: J Hum Hypertens Date: 2019-03-18 Impact factor: 3.012